Latest Ipilimumab Stories

2009-09-23 08:15:00

Researchers have made significant advances in the treatment of metastatic malignant melanoma – one of the most difficult cancers to treat successfully once it has started to spread – according to a study to be presented at Europe's largest cancer congress, ECCO 15 – ESMO 34 [1], in Berlin on Thursday.

2009-08-12 08:18:01

Patients with stage III or IV melanoma taking ipilimumab and the oral steroid budesonide to reduce side effects did not have less diarrhea, a known side effect of ipilimumab, according to results of a phase II trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

2009-08-03 11:06:00

SAN FRANCISCO, Aug. 3 /PRNewswire/ -- Biotech was "hot" in July driven by drug data, positive drug sales/earnings and partnering and M&A deals.

2009-06-20 08:11:18

Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug therapy that was used in combination with standardized hormone treatment and radiation therapy.

2009-06-19 22:27:46

Two patients with inoperable prostate cancer are cancer free, thanks in part to an experimental drug, U.S. doctors say. The Mayo Clinic physicians say this new approach caused the tumors to shrink dramatically and allowed surgery.

2009-04-30 05:00:00

PRINCETON, N.J., April 30 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today its financial results for the quarter ended March 31, 2009. Medarex's net loss for the quarter ended March 31, 2009 was $48.6 million, or ($0.38) per share.

2009-04-29 07:00:00

- Updated Survival and Biomarker Data for Ipilimumab to be Presented - PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc.

2009-04-20 07:00:00

PRINCETON, N.J., April 20 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced preliminary data from an ongoing Phase 1 clinical trial of MDX-1401 in patients with relapsed or refractory Hodgkin's lymphoma (HL) that demonstrated both clinical and immunological activity signals.

2009-04-14 07:00:00

WOBURN, Mass., April 14 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that its OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 study with OncoVEX (GM-CSF) in previously treated patients with Stage III and Stage IV melanoma had initiated.

Word of the Day
  • The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.
The word 'logocentrism' is a blend of logo- +‎ centrism.